Recursion Pharmaceuticals Inc (RXRX)
6.98
-0.18
(-2.51%)
USD |
NASDAQ |
Sep 27, 16:00
7.01
+0.03
(+0.43%)
After-Hours: 18:38
Recursion Pharmaceuticals Cash from Investing (Quarterly): -4.182M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -4.182M |
March 31, 2024 | -6.653M |
December 31, 2023 | -2.488M |
September 30, 2023 | -0.347M |
June 30, 2023 | -2.053M |
March 31, 2023 | -5.34M |
December 31, 2022 | -7.979M |
September 30, 2022 | 52.98M |
June 30, 2022 | 4.94M |
Date | Value |
---|---|
March 31, 2022 | 143.30M |
December 31, 2021 | -52.24M |
September 30, 2021 | -193.87M |
June 30, 2021 | -6.212M |
March 31, 2021 | -19.42M |
December 31, 2020 | -4.591M |
September 30, 2020 | -3.426M |
June 30, 2020 | -0.039M |
March 31, 2020 | -0.684M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-193.87M
Minimum
Sep 2021
143.30M
Maximum
Mar 2022
-6.017M
Average
-3.804M
Median
Cash from Investing (Quarterly) Benchmarks
Eli Lilly and Co | -2.199B |
Pfizer Inc | 4.60B |
Geron Corp | -36.15M |
United Therapeutics Corp | -80.00M |
Tonix Pharmaceuticals Holding Corp | 0.00 |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -82.22M |
Cash from Financing (Quarterly) | 263.12M |
Free Cash Flow | -345.60M |
Free Cash Flow Per Share (Quarterly) | -0.3567 |
Free Cash Flow to Equity (Quarterly) | -116.30M |
Free Cash Flow to Firm (Quarterly) | -86.40M |
Free Cash Flow Yield | -21.65% |